

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PURAPHARM CORPORATION LIMITED**

培力農本方有限公司

*(Formerly known as 培力控股有限公司 in Chinese)*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

**NOTICE OF BOARD MEETING**

The board of directors (the “**Board**”) of PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Tuesday, 29 March 2022, for the purposes of, among other things, considering and, if thought fit, approving the annual results of the Group for the year ended 31 December 2021 (the “**Annual Results**”), publication of the announcement for the Annual Results and considering the payment of a final dividend, if any.

By Order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 17 March 2022

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; the non-executive directors of the Company are Mr. Chow, Stanley and Mr. Cheong Shin Keong; and the independent non-executive directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.